Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vytrus Biotech's Revenue for the
six
months ended in Dec. 2025 was €3.99 Mil. Vytrus Biotech's average Accounts Receivable for the
six
months ended in Dec. 2025 was €1.15 Mil.
Hence, Vytrus Biotech's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.48.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vytrus Biotech Receivables Turnover Related Terms
Vytrus Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Vytrus Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (XMAD:VYT) has a Receivables Turnover of 3.48 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vytrus Biotech and its competitors. According to the industry distribution chart, Vytrus Biotech ranks #230 out of 841 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Vytrus Biotech's Receivables Turnover too high?
Vytrus Biotech's current Receivables Turnover is 3.48. The Biotechnology industry median Receivables Turnover is 5.27. Vytrus Biotech's value of 3.48 is 34% below this industry median. Based on the distribution chart, Vytrus Biotech ranks #230 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #230 out of 841 companies for Receivables Turnover. This puts Vytrus Biotech in the upper half of its industry. The industry median Receivables Turnover is 5.27. Vytrus Biotech's value of 3.48 is 34% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current Receivables Turnover of 3.48 is 34% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Receivables Turnover is 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.58, compared to a current price of €17.00 — trading 204.7% above its estimated fair value. The current Receivables Turnover is 3.48 and 34% below the Biotechnology industry median of 5.27. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Receivables Turnover is 3.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.00 is trading 204.7% above its estimated GF Value™ of €5.58.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Receivables Turnover: 3.48
GF Value™: €5.58 vs. price of €17.00 (204.7% above fair value)
Industry Position: 34% below the Biotechnology median (#230 of 841)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
